Advances and reflections on neoadjuvant immunotherapy for advanced gastric cancer
XU Ze-kuan
LI Feng-yuan
WU Hao
Abstract：Currently,chemotherapy combined with immune checkpoint inhibitors(ICIs)has become one of the important treatments for advanced gastric cancer or adenocarcinoma of esophagogastric junction.However,the effectiveness of this ap-proach in locally advanced gastric cancer has still not been val-idated by higher-level studies.The combination of molecular markers and personalised tests may be an effective means of screening the population for the benefits of immunotherapy in gastric cancer;The neoadjuvant immunotherapy regimen should take into account the specific type of tumour,molecular characteristics,and the patient's overall health status.Rou-tine evaluation after 2-4 cycles of neoadjuvant therapy com-bined with multidisciplinary team discussion can grasp the best timing during the whole treatment process and maintain the best interests of patients;The evaluation of the efficacy of neoadjuvant immunotherapy requires comprehensive judg-ment,and imaging and pathological evaluation are still subject to great controversy;The surgical interval of 4-6 weeks after neoadjuvant immunotherapy may be the optimal timing of sur-gery.The choice of surgery should take into account the loca-tion and size of the tumour,the patient's overall health status,and technical feasibility.Careful management and effective in-tervention of adverse events(IrAEs)during neoadjuvant immu-notherapy will help to improve the patient's outcome,and cli-nicians should closely monitor the patient's physical response throughout the course of the treatment and adjust the treatment regimen accordingly to ensure the best-balanced outcome.
Keywords：gastric cancerimmune checkpoint inhibitorsneoadjuvant therapy
Publication Date：2024-10-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 1109-1114 )